Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

RORĪ³ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment.

Liu X, Zawidzka EM, Li H, Lesch CA, Dunbar J, Bousley D, Zou W, Hu X, Carter LL.

Cancer Immunol Res. 2019 Jul;7(7):1054-1063. doi: 10.1158/2326-6066.CIR-18-0714. Epub 2019 May 7.

PMID:
31064778
2.

Synthetic RORĪ³ agonists regulate multiple pathways to enhance antitumor immunity.

Hu X, Liu X, Moisan J, Wang Y, Lesch CA, Spooner C, Morgan RW, Zawidzka EM, Mertz D, Bousley D, Majchrzak K, Kryczek I, Taylor C, Van Huis C, Skalitzky D, Hurd A, Aicher TD, Toogood PL, Glick GD, Paulos CM, Zou W, Carter LL.

Oncoimmunology. 2016 Nov 4;5(12):e1254854. doi: 10.1080/2162402X.2016.1254854. eCollection 2016.

Supplemental Content

Loading ...
Support Center